Natthida Khajornjiraphan1, Nyein Aye Thu1, Pierce Kah Hoe Chow2. 1. Department of General Surgery, Singapore General Hospital, Singapore. 2. Department of Surgical Oncology, National Cancer Centre, Singapore ; Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore ; Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore.
Abstract
BACKGROUND: Many patients with liver malignancies are not candidates for resection, and systemic therapies are often not effective. Radioembolization (RE) is an alternative treatment for this group of patients. The safety and efficacy of RE with yttrium 90 (Y90) in patients with hepatocellular carcinoma (HCC) or metastatic colon cancer to the liver have been proven in several studies. However, fewer studies have focussed on the safety and efficacy of RE with Y90 in other extrahepatic primary and secondary liver cancers. The effect on outcomes of concomitant use of Y90 with a systemic therapy is still currently under investigation. SUMMARY: A review of the published data on the use of RE as stand-alone, concomitant or sequential with other treatment modalities in HCC and other primary and secondary liver cancer is reported here. KEY MESSAGE: RE for the treatment of HCC and other extrahepatic, primary and secondary liver cancer has reasonable efficacy and acceptable toxicities. Definitive studies to establish the role of RE in the treatment of such malignancies are warranted.
BACKGROUND: Many patients with liver malignancies are not candidates for resection, and systemic therapies are often not effective. Radioembolization (RE) is an alternative treatment for this group of patients. The safety and efficacy of RE with yttrium 90 (Y90) in patients with hepatocellular carcinoma (HCC) or metastatic colon cancer to the liver have been proven in several studies. However, fewer studies have focussed on the safety and efficacy of RE with Y90 in other extrahepatic primary and secondary liver cancers. The effect on outcomes of concomitant use of Y90 with a systemic therapy is still currently under investigation. SUMMARY: A review of the published data on the use of RE as stand-alone, concomitant or sequential with other treatment modalities in HCC and other primary and secondary liver cancer is reported here. KEY MESSAGE: RE for the treatment of HCC and other extrahepatic, primary and secondary liver cancer has reasonable efficacy and acceptable toxicities. Definitive studies to establish the role of RE in the treatment of such malignancies are warranted.
Authors: Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: R Cianni; G Pelle; E Notarianni; A Saltarelli; P Rabuffi; O Bagni; L Filippi; E Cortesi Journal: Eur Radiol Date: 2012-07-27 Impact factor: 5.315
Authors: Yung-Hsiang Kao; Jeffrey D Steinberg; Young-Soon Tay; Gabriel Ky Lim; Jianhua Yan; David W Townsend; Charley A Budgeon; Jan A Boucek; Roslyn J Francis; Timothy St Cheo; Mark C Burgmans; Farah G Irani; Richard Hg Lo; Kiang-Hiong Tay; Bien-Soo Tan; Pierce Kh Chow; Somanesan Satchithanantham; Andrew Eh Tan; David Ce Ng; Anthony Sw Goh Journal: EJNMMI Res Date: 2013-07-25 Impact factor: 3.138
Authors: Aaron K T Tong; Yung Hsiang Kao; Chow Wei Too; Kenneth F W Chin; David C E Ng; Pierce K H Chow Journal: Br J Radiol Date: 2016-03-24 Impact factor: 3.039
Authors: Ieva Kurilova; Regina G H Beets-Tan; Jessica Flynn; Mithat Gönen; Gary Ulaner; Elena N Petre; F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Elisabeth G Klompenhouwer; Andrea Cercek; Nancy A Kemeny; Constantinos T Sofocleous Journal: Clin Colorectal Cancer Date: 2018-09-13 Impact factor: 4.481
Authors: Alessandro Cucchetti; Alberta Cappelli; Giorgio Ercolani; Cristina Mosconi; Matteo Cescon; Rita Golfieri; Antonio Daniele Pinna Journal: Liver Cancer Date: 2016-09-14 Impact factor: 11.740
Authors: Emrullah Birgin; Erik Rasbach; Steffen Seyfried; Nils Rathmann; Steffen J Diehl; Stefan O Schoenberg; Christoph Reissfelder; Nuh N Rahbari Journal: Cancers (Basel) Date: 2020-01-27 Impact factor: 6.639
Authors: Sebastian Mafeld; Peter Littler; Hannah Hayhurst; Derek Manas; Ralph Jackson; John Moir; Jeremy French Journal: J Gastrointest Cancer Date: 2020-03
Authors: R Gallicchio; A Nardelli; P Mainenti; A Nappi; D Capacchione; V Simeon; C Sirignano; F Abbruzzi; F Barbato; M Landriscina; G Storto Journal: Biomed Res Int Date: 2016-08-03 Impact factor: 3.411